Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CD PRIVATE EQUITY FUND III Net Asset Value 2020

Oct 13, 2020

64628_rns_2020-10-13_7a96167a-2a51-490d-a89a-7ffac3b90b31.pdf

Net Asset Value

Open in viewer

Opens in your device viewer

14 October 2020

==> picture [164 x 52] intentionally omitted <==

Cordish Dixon Private Equity Fund III (Fund)

ASX: CD3

NTA & Fund Update – 30 September 2020

NTA Update

The estimated unaudited net tangible asset (NTA) value after tax as at 30 September 2020 was $1.77[1,2] per unit (31 August 2020 was $1.72[2] per unit).

Between 31 August 2020 and 30 September 2020, the majority of the change in the estimated unaudited NTA can be attributed to foreign exchange movements. During this period, the Australian dollar depreciated against the US dollar by 2.90% to 0.7162 (from 0.7376 in August 2020).

Fund Update

Capital called

At 30 September 2020, US Select Private Opportunities Fund III L.P. ( LP ) has called US$88.5 million (or 77.6% of capital committed). The Fund’s proportionate share is approximately US$63.0 million (a 71.2% share).

Authorised for release by Walsh & Company Investments Limited (ACN 152 367 649, AFSL 410 433), the responsible entity of Cordish Dixon Private Equity Fund III.

  1. Based on estimated unaudited net tangible asset value before tax at 30 September 2020 of $1.79 per unit (31 August 2020 was $1.74)
  1. Source: Walsh & Company Investments Limited – the historical performance is not a guarantee of the future performance of the Fund.

The Cordish Dixon Private Equity Fund series comprise ASX listed and unlisted investment trusts focused on investing with and alongside leading, highly differentiated and specialised private equity funds focused on lower middle-market operating businesses in the US.

Level 15, 100 Pacific Highway North Sydney NSW 2060 cordishdixonfunds.com.au T 1300 454 801 F 1300 883 159 E [email protected] ARSN 612 132 813